无痛苦则无收获？明矾佐剂和单磷酰脂质 A 在百日咳和 HPV 疫苗中的辅助效应。
No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.
机构信息
The University of Louisville School of Medicine, Department of Microbiology and Immunology, Institute for Cellular Therapeutics, 570 S. Preston St., Donald Baxter Bldg., Louisville, KY 40202, USA.
The University of Louisville School of Medicine, Department of Microbiology and Immunology, Institute for Cellular Therapeutics, 570 S. Preston St., Donald Baxter Bldg., Louisville, KY 40202, USA.
出版信息
Curr Opin Immunol. 2017 Aug;47:17-25. doi: 10.1016/j.coi.2017.06.009. Epub 2017 Jul 17.
Abstract
Development of non-infectious subunit vaccines is hampered by a slow pipeline of new adjuvants to replace or enhance alum in part because expectations of safety are high. Transient vaccine side effects are not clinical priorities because they cause no lasting harm and vaccine development has appropriately been focused on avoidance of serious adverse events. As a result, surprisingly little is known about the extent to which side effects caused by a vaccine's reactogencicity are predictive of successful immunization outcomes. Recent clinical studies of pertussis and human papillomavirus vaccines adjuvanted with alum or the TLR4 agonist monophosphoryl lipid A can be used to advance understanding of the relationship between vaccine side effects and immunization outcomes.
摘要
非传染性亚单位疫苗的开发受到新佐剂的缓慢发展的阻碍，这些佐剂需要替代或增强明矾的作用，部分原因是安全性的期望很高。疫苗的短暂副作用并不是临床重点，因为它们不会造成持久的伤害，而且疫苗的开发已经适当侧重于避免严重的不良事件。因此，令人惊讶的是，人们对疫苗的反应原性引起的副作用在多大程度上可以预测免疫成功的结果知之甚少。最近对含有明矾或 TLR4 激动剂单磷酰脂质 A 的百日咳和人乳头瘤病毒疫苗的临床研究可以用来加深对疫苗副作用与免疫结果之间关系的理解。
相似文献
1
No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.无痛苦则无收获？明矾佐剂和单磷酰脂质 A 在百日咳和 HPV 疫苗中的辅助效应。
Curr Opin Immunol. 2017 Aug;47:17-25. doi: 10.1016/j.coi.2017.06.009. Epub 2017 Jul 17.
2
An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.一项评价四价人乳头瘤病毒（6/11/16/18 型）疫苗与白喉、破伤风、无细胞百日咳和脊髓灰质炎联合疫苗同时接种在 11 至 17 岁健康青少年中的安全性、耐受性和免疫原性的开放性、随机、多中心研究。
Pediatr Infect Dis J. 2010 Apr;29(4):314-8. doi: 10.1097/INF.0b013e3181c177fb.
3
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.南非 HIV 阳性女性中 HPV-16/18 AS04 佐剂疫苗的安全性和免疫原性：一项部分盲随机安慰剂对照研究。
Vaccine. 2013 Nov 19;31(48):5745-53. doi: 10.1016/j.vaccine.2013.09.032. Epub 2013 Oct 1.
4
Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.人乳头瘤病毒16/18 AS04佐剂疫苗在10至14岁女孩中的长期免疫原性和安全性：一项初始观察者设盲随机试验的6年开放随访
Pediatr Infect Dis J. 2014 Dec;33(12):1255-61. doi: 10.1097/INF.0000000000000460.
5
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.人乳头瘤病毒16/18 AS04佐剂疫苗在青春期女孩中按两剂方案接种的持续免疫原性：一项随机研究的五年临床数据及模型预测
Hum Vaccin Immunother. 2016;12(1):20-9. doi: 10.1080/21645515.2015.1065363. Epub 2015 Jul 15.
6
The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.佐剂增强 TdaP 疫苗免疫应答的潜力：MF59 和单磷酰脂质 A 的临床前评价。
Int J Pharm. 2015 Aug 15;492(1-2):169-76. doi: 10.1016/j.ijpharm.2015.06.030. Epub 2015 Jul 3.
7
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.AS04是一种基于铝盐和Toll样受体4（TLR4）激动剂的佐剂系统，可诱导短暂的局部先天性免疫反应，从而增强适应性免疫。
J Immunol. 2009 Nov 15;183(10):6186-97. doi: 10.4049/jimmunol.0901474. Epub 2009 Oct 28.
8
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.一种破伤风、白喉、重组无细胞百日咳联合疫苗（TdaP）在泰国健康成年人中的安全性和免疫原性。
Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555. Epub 2016 Sep 29.
9
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.人乳头瘤病毒 16/18 AS04 佐剂疫苗与破伤风类毒素、白喉类毒素和无细胞百日咳疫苗和/或脑膜炎球菌结合疫苗联合用于 11 至 18 岁健康女孩的免疫原性和安全性：一项随机开放试验的结果。
Pediatr Infect Dis J. 2011 Dec;30(12):e225-34. doi: 10.1097/INF.0b013e31822d28df.
10
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.HPV-16/18 AS04 佐剂宫颈癌疫苗与联合白喉破伤风无细胞百日咳灭活脊髓灰质炎疫苗共同接种于女童和年轻女性的免疫原性和安全性。
J Adolesc Health. 2010 Feb;46(2):142-51. doi: 10.1016/j.jadohealth.2009.11.205.
引用本文的文献
1
Molecular ingredients of an immunogen for long-lasting IgG.用于产生持久IgG的免疫原的分子成分。
Front Immunol. 2025 Aug 19;16:1639371. doi: 10.3389/fimmu.2025.1639371. eCollection 2025.
2
Innovative adjuvant strategies for next-generation pertussis vaccines.下一代百日咳疫苗的创新佐剂策略。
Hum Vaccin Immunother. 2025 Dec;21(1):2545636. doi: 10.1080/21645515.2025.2545636. Epub 2025 Aug 13.
3
Pre-Vaccination Immune Profiles and Responsiveness to Innate Stimuli Predict Reactogenicity and Antibody Magnitude Following mRNA Vaccination.接种疫苗前的免疫谱和对先天刺激的反应性可预测mRNA疫苗接种后的反应原性和抗体水平。
Vaccines (Basel). 2025 Jul 1;13(7):718. doi: 10.3390/vaccines13070718.
4
Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials.评估ID93+GLA-SE在接种卡介苗的健康成年人中的免疫原性和安全性：一项随机对照试验的系统评价和荟萃分析
Ther Adv Vaccines Immunother. 2025 Jun 5;13:25151355251344473. doi: 10.1177/25151355251344473. eCollection 2025.
5
Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development.利用免疫治疗分子和诊断生物标志物作为人源佐剂用于中东呼吸综合征冠状病毒疫苗开发。
Front Immunol. 2025 Mar 13;16:1538301. doi: 10.3389/fimmu.2025.1538301. eCollection 2025.
6
Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.针对人乳头瘤病毒（HPV）引发的宫颈癌的预防性疫苗：仍需要新型疫苗。
Infect Agent Cancer. 2025 Mar 10;20(1):16. doi: 10.1186/s13027-025-00643-5.
7
Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems.用作强大免疫调节生物材料载体系统的可生物降解聚合物。
Small. 2025 Feb 16:e2409422. doi: 10.1002/smll.202409422.
8
Association between Reactogenicity and Immunogenicity in a Vaccinated Cohort with Two mRNA SARS-CoV-2 Vaccines at a High-Complexity Reference Hospital: A Analysis on Immunology Aspects of a Prospective Cohort Study.在一家高复杂性参考医院接种两种mRNA新冠疫苗的队列中反应原性与免疫原性之间的关联：一项前瞻性队列研究的免疫学方面分析
Vaccines (Basel). 2024 Jun 17;12(6):665. doi: 10.3390/vaccines12060665.
9
Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions.纳米技术时代的癌症 mRNA 疫苗佐剂：策略、应用和未来方向。
J Nanobiotechnology. 2024 Jun 2;22(1):308. doi: 10.1186/s12951-024-02590-6.
10
BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.BECC438b Toll样受体4激动剂在小鼠攻毒模型中支持来自鼻内和肌肉注射的白百破疫苗的独特免疫反应谱。
Infect Immun. 2024 Mar 12;92(3):e0022323. doi: 10.1128/iai.00223-23. Epub 2024 Feb 7.
本文引用的文献
1
What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.百日咳疫苗免疫有何问题？为什么百日咳的免疫记忆失败了。
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):a029553. doi: 10.1101/cshperspect.a029553.
2
Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.二剂程序接种人乳头瘤病毒疫苗的应用 - 更新的免疫实践咨询委员会建议。
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408. doi: 10.15585/mmwr.mm6549a5.
3
Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation.疼痛与炎症中伤害感受器感觉神经元-免疫相互作用
Trends Immunol. 2017 Jan;38(1):5-19. doi: 10.1016/j.it.2016.10.001. Epub 2016 Oct 25.
4
Parents who refuse or delay HPV vaccine: Differences in vaccination behavior, beliefs, and clinical communication preferences.拒绝或延迟接种人乳头瘤病毒疫苗的父母：疫苗接种行为、观念及临床沟通偏好的差异
Hum Vaccin Immunother. 2017 Mar 4;13(3):680-686. doi: 10.1080/21645515.2016.1247134. Epub 2016 Oct 20.
5
Use of a Toxin Neutralization Assay To Characterize the Serologic Response to Adenylate Cyclase Toxin after Infection with Bordetella pertussis.使用毒素中和试验来表征百日咳博德特氏菌感染后对腺苷酸环化酶毒素的血清学反应。
Clin Vaccine Immunol. 2017 Jan 5;24(1). doi: 10.1128/CVI.00370-16. Print 2017 Jan.
6
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015.国家、地区、州和选定的局部地区 13-17 岁青少年疫苗接种覆盖率 - 美国，2015 年。
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):850-8. doi: 10.15585/mmwr.mm6533a4.
7
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.佐剂对蛋白抗原疫苗诱导的 CD4(+)T 细胞和 B 细胞应答的影响：一项 II 期、随机、多中心试验的结果。
Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25.
8
Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: Results from the Childhood National Immunization Coverage Survey, 2013.加拿大12至14岁女孩人乳头瘤病毒（HPV）未接种疫苗及拒绝接种疫苗的估计情况和决定因素：2013年全国儿童免疫接种覆盖率调查结果
Hum Vaccin Immunother. 2016 Jun 2;12(6):1484-90. doi: 10.1080/21645515.2016.1153207. Epub 2016 Mar 4.
9
Waning Tdap Effectiveness in Adolescents.青少年 Tdap 疫苗效力下降。
Pediatrics. 2016 Mar;137(3):e20153326. doi: 10.1542/peds.2015-3326. Epub 2016 Feb 5.
10
Vaccine Adjuvants: from 1920 to 2015 and Beyond.疫苗佐剂：从1920年到2015年及以后
Vaccines (Basel). 2015 Apr 16;3(2):320-43. doi: 10.3390/vaccines3020320.
Zotero 插件